Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4752880 | 0.74 | DAO (0.40) | CRBNDAOHTT | |
| SCHEMBL13934651 | 0.69 | DDB1 (0.50) | CRBNDAOHTT | |
| SCHEMBL3584096 | 0.69 | — | — | |
| SCHEMBL20201892 | 0.67 | — | — | |
| SCHEMBL9880650 | 0.64 | ERCC1 (0.49) | CRBN | |
| SCHEMBL23224166 | 0.64 | DAO (0.43) | CRBNDAO | |
| SCHEMBL13320099 | 0.64 | — | — | |
| SCHEMBL2986044 | 0.64 | DAO (0.46) | CRBNDAOHTT | |
| SCHEMBL45882 | 0.64 | DAO (0.43) | CRBNDAOHTT | |
| SCHEMBL4379234 | 0.64 | LMNA (0.46) | CRBNDAOHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160324881-A1 | Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer | ONCOPREVENT GMBH (DE) | 2016-11-10 | — | — | US | disclosed |
| US-20110086841-A1 | N-9 SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086841-A1 | N-9 SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ADORA3, ADORA2A, ADORA2B | CRBN 4698/4885DAO 471/4885HTT 2814/4885 |
| US-20160324881-A1 | Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer | TACR1, KISS1R, TACR2 | CRBN 3211/4885DAO 3307/4885HTT 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.